• Be A Partner
  • Social Responsibility
    • Students Training
  • IR
    • Investor Relations
    • Financial Charts
    • Annual Reports
  • News
    • PRESS RELEASES
    • SOCIAL EVENTS
    • CONFERENCES
  • Careers
  • Covid-19
  • Report a side effect
  • Contact Us
    • Branches
  • Home
  • We are Eipico
    We are Eipico
    EIPICO was established in Tenth of Ramadan City in 1980, with a capital of EGP 7 Million.
    • Uniqueness
      • WHO Approval
      • Sterile products Area
      • Automatic Ampoules Inspection
      • Eipico Ophthalmology
      • Primary packaging materials
      • Restricted-access barrier system
      • Distribution Channel
    • Our History
    • Vision, Mission & Values
    • Chairman Message
    • Eipico Employees
    • Manufacturing Facilities
    • Media Library
  • Global
    Global
    EIPICO is ranked Number 1 in Egyptian Exports of Pharmaceutical Products, capturing 29% of Egypt’s Total Exports of Pharmaceutical Products, by Value.
    • Eipico Destination
  • Manufacturing Facilities
    Manufacturing Facilities
    EIPICO is the Leading Egyptian Pharmaceutical Company, in Production, by Units. It is the Major Provider of Antibiotics, Lyophilized products and Spansule Capsules, to the Egyptian market.
    • Factory 1
    • Factory 2
    • Factory 3 (Biotechnology)
    • Eiaco Factory
    • Batterjee Factory
    • EIPICO Plastic Factory
  • R&D And Quality
    R&D And Quality
    EIPICO provides High Quality Pharmaceutical Products at reasonable prices, thus assisting human healthcare improvement .
    • Quality Assurance
    • Quality Control
    • R&D
    • Regulatory Affairs
    • Global Accreditation
    • Track and Trace
  • Products
    Products
    EIPICO produces 400 Pharmaceutical Products covering 25 therapeutic classes and it is the Major Provider of Antibiotics, Lyophilized products and Spansule Capsules, to the Egyptian market.
    • Eipico Products
      • By Alphabet
  • Biotechnology
Product Prescribing Information
You are here : > Products >> Eipico Products >Product Prescribing Information
CALCIUM CHLORIDE


Display

  • Prescription Information
  • Composition              

              

    Each 1 ml contains:
    Calcium chloride dihydrate ........................................................ 100 mg

                                                             

    Therapeutic Indications            

             

    Hypocalcemia.
    Electrolyte depletion.
    Cardiac arrest.
    Hyperkalemia.
    Hypermagnesemia.

                                                                                                                          

    Dosage and Administration          

                    

    Adults: 
    Hypocalcemia and Electrolyte depletion: 
    Intravenous 500 mg to 1 g administered slowly at a rate not to exceed 0.5 ml to 1 ml per minute. The dose can be repeated at 1-3-days intervals according to serum calcium concentrations.
    Cardiac arrest: 
    Intravenous 500 mg to 1 g administered at a rate not to exceed 1 ml per minute.
    Intraventricular, 200 mg-400 mg administered directly into cavity as a single dose.
    Hyperkalemia: 
    Dosage must be titrated by constant monitoring of E.C.G. changes during administration.
    Hypermagnesenia: 
    Intravenous 500 mg, repeated as indicated by patient response.
    Pediatrics:
     Hypocalcemia:
    Intravenous 25 mg/kg.

                                                           

    Contraindications         

                 

    As for all parenteral calcium salts, digitatis toxicity and ventricular fibrillation during cardiac resuscitation.

                                                               

    Warnings and Precautions     

                  

    Calcium chloride is irritant and cause necrosis if Injected I.M..

                                                  

    Drug Interactions                 

            

    Concurrent use of parenteral calcium salts with digitalis may increase the risk of cardiac arrhythmias.
    Parenteral calcium salts may neutralize effects of parenteral magnesium sulfate.
    Parenteral calcium salts reverse the effects of non-depolarizing neuromuscular blocking agents.
    Parenteral calcium salts should be administered cautiously in patients receiving potassium-containing medications because of danger of precipitating cardiac arrhythmias.

                                                  

    Pregnancy and Lactation       

                

    Pregnancy:
    studies have not been done in either animals or humans.
    Lactation:
     It is not known whether calcium chloride is excreted in breast milk . 

                                                          

    Undesirable Effects         


     Intravenous administration may cause flushing, nausea, vomiting, sweating, skin rash, hypotension and irregular heart beats.

                                                                                                              

    Pharmacological Properties 

                          

    Calcium is essential for the functional integrity of the nervous, muscular and skeletal systems.
    It plays a role in normal cardiac function, renal function, respiration, blood coagulation and cell membrane and capillary permeability.
    When there is disturbance in the calcium balance due to any cause, the stores of calcium in bone may be depleted to fill the body's more acute needs.

                                                           

    Packaging                 


    CALCIUM CHLORIDE Ampoules: Boxes containing 5, 10, 50, or 100 ampoules of 5 and 10 ml each.




WE ARE EIPICO

  • Uniqueness
  • Our History
  • Vision, Mission & Values
  • Chairman Message
  • Eipico Employees

Manufacturing Facilities

  • Factory 1
  • Factory 2
  • Factory 3
  • Eiaco Factory
  • Batterjee Factory
  • Plastic Factory

Products

  • Eipico Product
  • Eipico Products By Alphabet

Contact Us

EIPICO, Tenth of Ramadan City - 1st Industrial Zone B1, Egypt.

Telephone : +20554499199
Fax : +20554499306

eipico@eipico.com.eg

Back to top
Powered by EIPICO Team
    Visitors Count : 767397